NCT07477223

Brief Summary

Test whether a doctor-formulated protein made from real beef is more digestible than standard whey protein powder. For the first 30 days, participants receive either standard whey protein powder or Equip Protein and track how the gut responds weekly. At the 30 day mark, all participants receive the standard Equip protein to track differences in digestability.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Feb 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 6, 2026

Completed
18 days until next milestone

First Submitted

Initial submission to the registry

February 24, 2026

Completed
21 days until next milestone

First Posted

Study publicly available on registry

March 17, 2026

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 6, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 6, 2026

Completed
Last Updated

May 28, 2026

Status Verified

May 1, 2026

Enrollment Period

4 months

First QC Date

February 24, 2026

Last Update Submit

May 26, 2026

Conditions

Keywords

digestiongutbloating

Outcome Measures

Primary Outcomes (4)

  • PROMIS® Scale v1.0 - Gastrointestinal Constipation 9a

    Outcome Measure Description: Change from baseline in gastrointestinal constipation as assessed by the Patient-Reported Outcomes Measurement Information System® (PROMIS®) Gastrointestinal Constipation 9a Scale, Version 1.0, which evaluates constipation frequency, severity, and impact over the past 7 days. Scoring: Each item is scored 1-5; total raw scores are converted to a T-score metric (range \~25-85). Higher scores indicate more severe constipation (worse outcome).

    Change from baseline (Day 1-5) in gastrointestinal constipation at 4 weeks after the start of the intervention (Day 25-35)

  • PROMIS® Scale v1.0 - Gastrointestinal Belly Pain 5a Survey

    Outcome Measure Description: Change from baseline in gastrointestinal belly pain as assessed by the Patient-Reported Outcomes Measurement Information System® (PROMIS® Gastrointestinal Belly Pain 5a Scale, Version 1.0), measuring frequency and intensity of abdominal pain over the past 7 days. Scoring: Each item scored 1-5; T-score conversion range \~25-80. Higher scores indicate more severe belly pain (worse outcome).

    Change from baseline (Day 1-5) in gastrointestinal belly pain at 4 weeks after the start of the intervention (Day 25-35)

  • PROMIS® Scale v1.0 - Gastrointestinal Bowel Incontinence 4a Survey

    Outcome Measure Description: Change from baseline in gastrointestinal bowel incontinence as assessed by the Patient-Reported Outcomes Measurement Information System® (PROMIS® Gastrointestinal Bowel Incontinence 4a Scale, Version 1.0), evaluating frequency and impact of bowel incontinence over the past 7 days. Scoring: Each item scored 1-5; T-score conversion range \~25-80. Higher scores indicate more severe bowel incontinence (worse outcome).

    Change from baseline (Day 1-5) in gastrointestinal bowel incontinence at 8 weeks after the start of the intervention (Day 55-65)

  • PROMIS Scale v1.1 - Gastrointestinal Gas and Bloating 13a

    Outcome Measure Description: Change from baseline in gastrointestinal gas and bloating as assessed by the Patient-Reported Outcomes Measurement Information System® (PROMIS® Gastrointestinal Gas and Bloating 13a Scale, Version 1.1), which evaluates frequency and intensity over the past 7 days. Scoring: Each item scored 1-5; T-score conversion range \~25-85. Higher scores indicate more severe gas and bloating (worse outcome).

    Change from baseline (Day 1-5) in gastrointestinal gas and bloating at 4 weeks after the start of the intervention (Day 25-35)

Study Arms (2)

Crossover longitudinal where participants act as their own control - whey arm

SHAM COMPARATOR

30 % of participants receive a standard chocolate whey protein, followed by the Equip chocolate beef protein.

Dietary Supplement: Beef proteinDietary Supplement: Chocolate whey protein

Crossover longitudinal where participants act as their own control - beef arm

EXPERIMENTAL

70 % of participants receive Equip chocolate protein followed by another Equip chocolate protein.

Dietary Supplement: Beef protein

Interventions

Beef proteinDIETARY_SUPPLEMENT

Original beef protein powder chocolate flavor, manufactured by Equip, packed with 21g of complete protein, plus naturally occurring collagen and gelatin

Crossover longitudinal where participants act as their own control - beef armCrossover longitudinal where participants act as their own control - whey arm
Chocolate whey proteinDIETARY_SUPPLEMENT

Whey protein isolate is a dairy-derived protein powder containing ≥90% protein by weight, with minimal lactose and fat. The product is provided as a flavored powder and administered orally when mixed with water. The product does not contain added bioactive ingredients beyond standard whey protein isolate.

Crossover longitudinal where participants act as their own control - whey arm

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Can read and understand English.
  • US resident.
  • Willing and able to follow the requirements of the protocol.
  • Willing to purchase study materials.

You may not qualify if:

  • Individuals with Beef Allergy
  • Individuals with Whey Allergy
  • Individuals with Dairy Allergy
  • Individuals with Serious Digestive Disorders
  • Individuals on a Vegan Diet
  • Individuals with Chronic Kidney Disease
  • Pregnant or Nursing Individuals
  • Individuals with Gout

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Efforia

New York, New York, 10003, United States

Location

Related Links

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
Protein powders have individually been packaged into indeterminate packages so that participants are unaware of which product they are testing. They are informed prior to study start that they may be given whey or beef protein.
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
CROSSOVER
Model Details: Crossover observational where participants act as their own control
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 24, 2026

First Posted

March 17, 2026

Study Start

February 6, 2026

Primary Completion

June 6, 2026

Study Completion

June 6, 2026

Last Updated

May 28, 2026

Record last verified: 2026-05

Locations